Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype.

Bender AM, Weiner RL, Luscombe VB, Cho HP, Niswender CM, Engers DW, Bridges TM, Conn PJ, Lindsley CW
Bioorg Med Chem Lett. 2017 27 (11): 2479-2483

PMID: 28427812 · PMCID: PMC5508519 · DOI:10.1016/j.bmcl.2017.04.009

This letter describes the synthesis and structure activity relationship (SAR) studies of structurally novel M antagonists, based on a 4,6-disubstituted core, identified from a high-throughput screening campaign. A multi-dimensional optimization effort enhanced potency at both human and rat M (ICs<300nM), with no substantial species differences noted. Moreover, CNS penetration proved attractive for this series (brain:plasma K=0.87), while other DMPK attributes were addressed in the course of the optimization effort, providing low in vivo clearance in rat (CL=5.37mL/min/kg). Surprisingly, this series displayed pan-muscarinic antagonist activity across M, despite the absence of the prototypical basic or quaternary amine moiety, thus offering a new chemotype from which to develop a next generation of pan-muscarinic antagonist agents.

Copyright © 2017 Elsevier Ltd. All rights reserved.

MeSH Terms (12)

Animals Brain Humans Inhibitory Concentration 50 Muscarinic Antagonists Protein Binding Pyrimidines Rats Receptor, Muscarinic M4 Receptors, Muscarinic Recombinant Proteins Structure-Activity Relationship

Connections (1)

This publication is referenced by other Labnodes entities: